Skip to main content
Home
Issues
Issue Archive
Topics
Conference Correspondent
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
Issue Archive
Topics
Conference Correspondent
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
ASH 2019 - Chronic Lymphocytic Leukemia
ASH 2019 - Chronic Lymphocytic Leukemia
Alliance A041702 Phase 3 Study Comparing Ibrutinib + Obinutuzumab versus Ibrutinib + Venetoclax + Obinutuzumab in Untreated, Older Patients with CLL
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab for First-Line Treatment of CLL with IGHV Mutation and without Del(17p)/Mutated TP53
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
ELEVATE TN: Results of a Phase 3 Study of Acalabrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma
Read More
1
2
Page 2 of 2
Results 11 - 18 of 18
